atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

NEXT STORY
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus
PREV STORY
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments

author_avatar
NASDAQ Market News

Sharps Compliance Reports Fiscal 2019 Second Quarter Results

Second quarter 2019 revenue increased to $12.4 million with gross margin of 32%, net ...

author_avatar
NASDAQ Market News

Orthopedic Implants Market Size to Reach US $64 Billion by 2026; Rising Number of Orthopedic Sports Injuries to Favor Growth

author_avatar
NASDAQ Market News